Acebilustat is under clinical development by Celtaxsys Inc and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Acebilustat’s likelihood of approval (LoA) and phase transition for Primary Ciliary Dyskinesia took place on 25 Nov 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Acebilustat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Acebilustat (formerly CTX-4430, EP-501) is under development for the treatment of bullous dermatoses, upper extremity lymphedema and primary ciliary dyskinesia. CTX-4430 is a small molecule which is administered through oral and topical routes. It acts by targeting pro-inflammatory enzyme leukotriene A4 hydrolase (LTA4H).
It was also under development for the treatment of acne vulgaris, adult cystic fibrosis as an oral and topical formulation. It was under development for acne rosacea as a topical formulation. It was also under development for the treatment of gouty arthritis, hidradenitis suppurativa and non-CF bronchiectasis. and pulmonary arterial hypertension as oral formulation, and was also under development for the treatment of an unspecified indication as topical formulation.
Celtaxsys Inc overview
Celtaxsys Inc (Celtaxsys) is a clinical-stage pharmaceutical development company.
Quick View Acebilustat LOA Data
|Highest Development Stage|